Back to Dashboard
31

ESTA

๐Ÿฅ Healthcare

Establishment Labs Holdings Inc.

Conservative #1070Aggressive #459Moderate RiskHigh 98
$74.28-5.12%
Day High$78.00
Day Low$74.28
Volume0.2M
Mkt Cap$2.2B
52W Low $2752W High $78
Market Cap
$2.2B
P/E Ratio
N/A
Rev Growth
0.5%
Sector avg: 161.5%
Earnings Growth
-7.8%
Profit Margin
-43.5%
Sector avg: -3292.7%
Debt/Equity
15.96

Why This Score

ESTA scores 30.6 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Strengths
  • High conviction (98/100) โ€” fundamental and ML signals agree on this stock.
Risk Factors
  • Liquidity concern: Limited trading volume or float results in a 2-point penalty for execution risk.
  • Above-average volatility (16.9%) may not suit conservative risk tolerance.
  • Elevated leverage (D/E 15.96) increases financial risk in a rising-rate environment.

Moderate penalties (-5.0 points) reflect identified risk factors. The overall score balances these against the stock's fundamental strengths.

Score Breakdown

Overall Score30.6
Fundamental Score28.9
ML Score42.0

Score by Horizon

3 Month
50.4
6 Month
56.3
Primary
1 Year
59.3

Quality Assessment

A
Earnings Grade
Strong fundamentals, high earnings quality
Quality Flags
Extreme leverage: D/E ratio of 16.0x โ€” balance sheet risk
Speculative Classification
Speculative growth โ€” negative margins and ROE with momentum-driven price action. High risk of mean reversion.
Conservative score reduced by 3 points.

Position Sizing

Suggested Allocation
4.7%
Confidence
high

Score Composition Waterfall

How each component affects the final score
Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)
Weinstein (12.1%)
100
Advancing
Sentiment (2.5%)
71
Positive
Analyst (6.4%)
71
Favorable
Tradability (post-hoc)
76
Grade B
Base
26.6
SHAP
+0.5
Factors
+0.9
Conviction
+2.6
Final
30.6
Positive adjustment
Negative adjustment
Base blend
Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)32.0
Technical (Momentum, Weinstein, Volatility)83.0
External (Sentiment, Analyst, Macro)86.0
Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score
Features
Confidence
Feature Coverage89%

Growth Estimates

Short-term
-0.3% to +4.0%
Medium-term
+0.4% to +7.1%
Long-term
+1.2% to +10.1%

ML Model Core Features100 trained inputs โ†’ ML Score: 42

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence
Consensus Score71.4/100
Target Upside+13.6%
Coverage14 analysts
Market Sentiment
Sentiment Score71.2/100
News Volume1 articles
Technical Stage
Weinstein Stage2 โ€” Advancing
12M Momentum+0.7%
6M Momentum+0.8%
Volatility+0.2%
Momentum & Technical
Momentum Acceleration-6.8%
Momentum ConsistencyStrong (0.92)
Relative Strength vs Sector+49.6%
Trend Strength (ADX Proxy)Strong (4.4)
Momentum Quality+0.550
Momentum BreadthBroad โœ“
Macro Regime
Bull RegimeYes
High Vol RegimeNo
S&P 500 Return+25.0%
Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal
5%
Low risk
Sector RevGr Rank
P43
Revenue growth vs Healthcare peers
Sector PE Rank
P22
Valuation vs Healthcare peers
Sector FCF Rank
P42
Free cash flow vs Healthcare peers
Growth Deviation
-0.0ฯƒ
Z-score vs sector median
Stagnation Flag
NO
Not flagged

Analysis Signals

Scoring Factors
Fundamental score of 58 relative to sector peers58/100
Machine learning model ranks this stock at the 59th percentileP59
ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight
SHAP feature alignment: +0.6pt (features align with model priorities)โ€”
Blend: 91% fund (58.5) + 9% ML (57.6) + SHAP(+0.6) = 59.0โ€”
Factor quality: +1.2pt (multi-factor composite)โ€”
Risk assessment: moderate. Annualized volatility 16.9%. Max drawdown 26% (-7.1 pts)Moderate
Market cap adjustment: -4.0 points ($2.2B market cap)-4.0 pts
Conviction bonus: +3.4pt (conviction=98)โ€”
Risk Factors
Earnings quality grade A: strong earnings quality and financial health. Score adjusted by -10 pointsGrade A
Quality concern: Extreme leverage: D/E ratio of 16.0x โ€” balance sheet riskFlag

Sector Peer Comparison(Healthcare โ€” Rank #189 of 344 stocks)

StockScoreP/ERev GrowthMarginMkt Cap
ESTA30.6N/A0.5%-43.5%$2.2B
INCY89.915.821.2%25.0%$19.6B
GMAB86.113.122.8%36.4%$17.9B
CPRX83.713.723.5%37.6%$3.0B
EXEL78.315.17.0%33.7%$11.9B
ASND78.216.698.0%-31.7%$13.8B
VRTX78.232.18.9%32.9%$121.8B
NBIX75.126.521.4%16.7%$13.1B
RPRX75.025.15.1%32.4%$19.3B
HOLX74.831.11.7%13.8%$16.8B
AMGN74.226.010.0%21.0%$204.8B
ARGX73.735.178.6%38.0%$47.4B
REGN73.019.41.0%31.4%$80.2B
ALKS72.916.5-6.4%23.9%$5.0B
ISRG72.761.720.5%28.4%$180.9B
KRYS71.541.4473.0%30.7%$7.9B
Sector Average36.441.9161.5%-3292.7%โ€”

Market Sentimentvia FMP

Company Overviewvia FMP

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

CEO
Fillipo Peter Caldini
Employees
1,034
Beta
0.99
Industry
Medical - Devices
FMP-Identified Peers

Technical Picturecomputed from daily prices

RSI (14)
68.1
Neutral
Trend
Bullish
10-day vs 50-day MA
From 52W High
-10.8%
High: $83.31
From 52W Low
+179.9%
Low: $26.56
Moving Averages
10-Day
$75.80
Below
20-Day
$72.90
Above
50-Day
$71.20
Above
200-Day
$52.10
Above
60-Day Support
$62.77
60-Day Resistance
$83.31
Weinstein Stage Analysisbased on 200-day SMA framework
Stage 2 โ€” AdvancingScore: 90/100

Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.

Favorable technical position; 50-day SMA acts as support
Price vs 200 SMA
+42.7%
200 SMA Slope (60d)
+25.6%
Rising
Volume Ratio
1.24x
10d avg vs 50d avg
Days in Stage
100
Confidence: 90%

Financial Statementslast 4 quarters via FMP

MetricQ4 2025Q3 2025Q2 2025Q1 2025
Revenue$65M$54M$51M$41M
Gross Profit$46M$38M$35M$28M
Operating Income$-4M$-4M$-14M$-17M
Net Income$-3M$-11M$-17M$-21M
EPS (Diluted)$-0.09$-0.38$-0.56$-0.70
Gross Margin70.5%70.1%68.8%67.2%
Operating Margin-6.1%-7.5%-27.5%-41.0%
Net Margin-4.0%-20.7%-32.3%-50.1%

Why This Stock

Healthcare

Tradability FilterGrade B โ€” 76/100Score impact: -42.0pt

Volume
76
462K avg/day
Dollar Vol
90
$35M/day
Float
56
26M shares
Mkt Cap
60
$2.2B
Range
100
195% spread
Composite Liquidity Score76/100
FDCBA

Multi-Year Range Analysis

Sideways: 0/100
YearLowHighRangeStatus
2021$53.25$88.6649.9%Wide
2022$44.03$93.8072.2%Wide
2023$16.96$79.88129.9%Wide
2024$24.42$60.1284.5%Wide
2025$26.56$78.2498.6%Wide
3-Year Range
129.9%
Narrow Years
0 / 5
Sideways Penalty
None
Free Float
90.3%
Outstanding Shares
29M
Bid-Ask Spread
195.0%
Institutional Tradable
Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.